PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.37_2629
Abstract: Karyopharm Therapeutics, Kite Pharma, Lundbeck, Merck, Roche/Genentech, Inc., Seattle Genetics, Takeda, Teva, TG Therapeutics; Research Funding: Roche/Genentech, Inc. Sharman, J: Consultant Advisory Role: Pharmacyclics, Celgene, TG Therapeutics, Genentech, Inc., AbbVie, Acerta Pharma/AstraZeneca; Research Funding: Pharmacyclics,… read more here.
Keywords: gilead sciences; study; genentech inc; oncology ... See more keywords
995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1181
Abstract: DISCOVER is an ongoing trial comparing emtricitabine plus tenofovir alafenamide (F/TAF) or tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP). DISCOVER included some participants already taking F/TDF for PrEP at baseline (BL) creating a… read more here.
Keywords: gilead sciences; sciences inc; research; prep ... See more keywords
103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.413
Abstract: Background: Daily F/TDF is highly effective for HIV pre-exposure prophylaxis (PrEP). Prior studies have found that women and people of younger age have lower adherence and lower persistence on PrEP, yet real-world evidence describing persistence… read more here.
Keywords: gilead sciences; sciences inc; prep; non persistence ... See more keywords
P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.205
Abstract: Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 inhibitor that has shown good efficacy and was well tolerated for treatment of rheumatoid arthritis (RA). The objective of this study was to evaluate efficacy… read more here.
Keywords: gilead sciences; shareholder; sciences inc; gilead ... See more keywords
P216 Effects of filgotinib on anaemia, thrombocytopoenia and leukopoenia: results from a Phase 3 study in patients with active RA and prior inadequate response or intolerance to bDMARDs
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.211
Abstract: Cytopoenias are common in patients treated for rheumatoid arthritis (RA) with non-janus kinase 1 (JAK1)-selective inhibitors, possibly due to JAK2-mediated haematopoietic growth factor inhibition. We investigated the extent of cytopoenia in patients with active RA,… read more here.
Keywords: gilead sciences; sciences inc; shareholder; employee ... See more keywords
THU0014 TARGETING ACTIVATED ASK1 IN SYNOVIAL FIBROBLASTS IN COMBINATION WITH JAK1 INHIBITION ENHANCES EFFICACY IN RAT CIA
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2145
Abstract: Background: Despite improved therapy, rheumatoid arthritis (RA) remains an area of unmet medical need. Current therapies have improved disease control by targeting inflammatory pathways. However, treatments rarely induce remission, highlighting the need for new therapies.… read more here.
Keywords: gilead sciences; sciences inc; combination; inhibition ... See more keywords
THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2325
Abstract: Background Filgotinib (FIL) is an oral selective Janus kinase 1 (JAK1) inhibitor being developed to treat inflammatory diseases. Objectives This phase 1 study evaluated the pharmacokinetics (PK) and short-term safety of FIL in subjects with… read more here.
Keywords: gilead sciences; sciences inc; employee gilead; subjects moderate ... See more keywords
THU0194 SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB MODULATES THE DISEASE-ASSOCIATED WHOLE BLOOD TRANSCRIPTIONAL PROFILE OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2509
Abstract: Background Filgotinib (FIL), an oral selective JAK1 inhibitor, was safe and efficacious in FINCH2, a randomized, double-blind, placebo-controlled, phase 3 study in patients with active rheumatoid arthritis (RA) who had an inadequate response to biologic… read more here.
Keywords: gilead sciences; sciences inc; gilead; fil ... See more keywords
THU0017 IN VITRO MECHANISTIC STUDIES DEMONSTRATE FILGOTINIB ACTIVITY THAT HAS POTENTIAL IMPLICATIONS FOR DIFFERENTIATION AMONG JAK INHIBITORS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3361
Abstract: Background Inhibition of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway has demonstrated efficacy in immune-mediated diseases and has been identified as a therapeutic target for the treatment of rheumatoid arthritis (RA). Differences… read more here.
Keywords: gilead sciences; sciences inc; inhibition; cell ... See more keywords
FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2901
Abstract: Background: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain and fatigue, along with maintenance of physical function, and improvement… read more here.
Keywords: fatigue; pain; gilead sciences; sciences inc ... See more keywords
SAT0155 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN MTX-NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) (FINCH3)
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.3949
Abstract: Background: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in multiple phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA). We have previously described the molecular response to FIL… read more here.
Keywords: employee gilead; mtx; gilead sciences; sciences inc ... See more keywords